Teva Pharmaceutical Industries Limited (NASDAQ: TEVA) had a rough 2011. If the pre-market trading indications manage to last throughout the day, then it appears that Teva could be off to a great start in 2012. The company just announced that it will have a new Chief Executive Officer. Whether you look at Teva for its generic gains or its branded products, this may matter. The company’s current CEO will retire in May and will be replaced by Jeremy Levin upon retirement. Teva was well above $50 throughout much of early 2011 and ended up going under $40.00 before recovering. Shares closed out at $40.36 on Friday and the stock is indicated up 3.6% at $41.82 so far this Tuesday morning to start of 2012.
JON C. OGG
In 20 Years, I Haven’t Seen A Cash Back Card This Good
After two decades of reviewing financial products I haven’t seen anything like this. Credit card companies are at war, handing out free rewards and benefits to win the best customers.
A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges.
Our top pick today pays up to 5% cash back, a $200 bonus on top, and $0 annual fee. Click here to apply before they stop offering rewards this generous.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.